Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.53 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | TDO2 | P48775 | 2/20 | 0.45 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20555905 | 1.00 | IDO1 (0.53) | IDO1CYP2C9NR1I2CYP2C8CYP3A4 | |
| SCHEMBL17730141 | 1.00 | IDO1 (0.53) | IDO1CYP2C9NR1I2CYP2C8CYP3A4 | |
| SCHEMBL21836475 | 0.92 | IDO1 (0.45) | IDO1CYP2C9NR1I2CYP2C8CYP3A4 | |
| SCHEMBL21836477 | 0.92 | IDO1 (0.45) | IDO1CYP2C9NR1I2CYP2C8CYP3A4 | |
| SCHEMBL23801454 | 0.92 | IDO1 (0.51) | IDO1CYP2C9NR1I2CYP2C8CYP3A4 | |
| SCHEMBL19900635 | 0.92 | IDO1 (0.51) | IDO1CYP2C9NR1I2CYP2C8CYP3A4 | |
| SCHEMBL21836548 | 0.89 | IDO1 (0.55) | IDO1CYP2C9NR1I2CYP2C8CYP3A4 | |
| SCHEMBL17730122 | 0.89 | IDO1 (0.55) | IDO1CYP2C9NR1I2CYP2C8CYP3A4 | |
| SCHEMBL17730120 | 0.89 | IDO1 (0.55) | IDO1CYP2C9NR1I2CYP2C8CYP3A4 | |
| SCHEMBL17729117 | 0.87 | IDO1 (0.56) | IDO1CYP2C9CYP2C8CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351164-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-07 | — | — | US | disclosed |
| US-11337970-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210290613-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-09-23 | — | — | US | disclosed |
| US-20210283123-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-09-16 | — | — | US | disclosed |
| US-11066392-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-20 | — | — | US | disclosed |
| CN-106999450-B | Immunomodulator | 弗莱塞斯生物科学公司 | 2021-07-09 | — | — | CN | disclosed |
| EP-3215142-B1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20200095231-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2020-03-26 | — | — | US | disclosed |
| EP-3503891-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | Bristol-Myers Squibb Company (US) | 2019-07-03 | — | — | EP | disclosed |
| US-10206893-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180325889-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2018-11-15 | — | — | US | disclosed |
| WO-2018039512-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-01 | — | — | WO | disclosed |
| EP-3215142-A2 | IMMUNOREGULATORY AGENTS | Flexus Biosciences, Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20170143649-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2017-05-25 | — | — | US | disclosed |
| US-9598422-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160137653-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2016-05-19 | — | — | US | disclosed |
| WO-2016073774-A2 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137653-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2655/4885NR1I2 1752/4885 |
| US-10206893-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2655/4885NR1I2 1752/4885 |
| US-20170143649-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2655/4885NR1I2 1752/4885 |
| US-11351164-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2152/4885NR1I2 2516/4885 |
| US-20180325889-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2655/4885NR1I2 1752/4885 |
| US-20210283123-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2152/4885NR1I2 2516/4885 |
| US-11337970-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2175/4885NR1I2 2606/4885 |
| US-11066392-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2175/4885NR1I2 2606/4885 |
| US-20200095231-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2175/4885NR1I2 2606/4885 |
| US-20210290613-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2175/4885NR1I2 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.